Ironwood Pharmaceuticals Inc - Ordinary Shares - Class A

NASDAQ:IRWD

10.61

-0.23 (-2.12%)

Market Cap (Intraday)	1.71B
Current PE	16.08
Forward PE	12.06
2yr Forward PE	10.61

See more stats

Estimates Current Quarter

Revenue	$87.94 Million
Adjusted EPS	$0.22

See more estimates

10-Day MA	N/A
50-Day MA	N/A
200-Day MA	N/A

See more pivots

Ironwood Pharmaceuticals, Inc. Stock, NASDAQ:IRWD

100 Summer Street, Suite 2300, Boston, Massachusetts 02110

United States of America

Phone: +1.617.621.7722

Number of Employees: 232

http://www.ironwoodpharma.com

Description

Ironwood Pharmaceuticals, Inc. is a commercial biotechnology company, which engages in the discovery, commercialization, and development of medicines. Its products include linaclotide, a guanylate cyclase type-C agonists which treats patients irritable bowel syndrome with constipation and chronic constipation. The company was founded by Peter M. Hecht, Eric F. Summers, G. Todd Milne, Brian M. Cali, Joseph C. Cook Jr., and Gina Bornino Miller on January 5, 1998 and is headquartered in Boston, MA.